Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis

被引：0
|
作者：
Pardanani, A. D.
Caramazza, D.
George, G.
Lasho, T. L.
Hogan, W. J.
Litzow, M. R.
Begna, K.
Hanson, C. A.
McClure, R. F.
Bavisotto, L. M.
Smith, G.
Kowalski, M.
Sirhan, S.
Roberts, A. W.
Gupta, V.
Gotlib, J.
Tefferi, A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Porta Clin PLLC, Seattle, WA USA
[3] YM BioSci, Mississauga, ON, Canada
[4] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[5] Royal Melbourne Hopsital, Parkville, Vic, Australia
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
    A Pardanani
    T Lasho
    G Smith
    C J Burns
    E Fantino
    A Tefferi
    Leukemia, 2009, 23 : 1441 - 1445
  • [22] CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway
    Wang, Xin
    Lu, Jie
    Li, Jing
    Liu, Yang
    Guo, Gaochao
    Huang, Qiang
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [23] CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
    Pardanani, A.
    Lasho, T.
    Smith, G.
    Burns, C. J.
    Fantino, E.
    Tefferi, A.
    LEUKEMIA, 2009, 23 (08) : 1441 - 1445
  • [24] Enhanced antitumor activity of cetuximab in combination with the Jak inhibitor CYT387 against non-small-cell lung cancer with various genotypes
    Hu, Y.
    Dong, X.
    Liu, P.
    Liu, X.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S3 - S3
  • [25] Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes
    Hu, Yuan
    Dong, Xian-Zhe
    Liu, Xu
    Liu, Ping
    Chen, Yi-Bang
    MOLECULAR PHARMACEUTICS, 2016, 13 (02) : 689 - 697
  • [26] Drug repositioning of TANK-binding kinase 1 inhibitor CYT387 as an alternative for the treatment of Gram-negative bacterial sepsis
    Lee, Seung Jun
    Gharbi, Amal
    You, Jueng Soo
    Han, Hee Dong
    Kang, Tae Heung
    Hong, Seong Hwi
    Park, Won Sun
    Jung, In Duk
    Park, Yeong-Min
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 73 : 482 - 490
  • [27] CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway
    Xin Wang
    Jie Lu
    Jing Li
    Yang Liu
    Gaochao Guo
    Qiang Huang
    Journal of Translational Medicine, 19
  • [28] Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason R.
    Jamieson, Catriona
    Cortes, Jorge E.
    Talpaz, Moshe
    Stone, Richard M.
    Silverman, Michael H.
    Gilliland, D. Gary
    Shorr, Jolene
    Tefferi, Ayalew
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) : 789 - 796
  • [29] P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387
    Durmus, S.
    Xu, N.
    Sparidans, R. W.
    Wagenaar, E.
    Beijnen, J. H.
    Schinkel, A. H.
    PHARMACOLOGICAL RESEARCH, 2013, 76 : 9 - 16
  • [30] P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) restrict the brain penetration of the Janus family of tyrosine kinase (JAK) inhibitor CYT387
    Durmus, Selvi
    Xu, Ning
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    FASEB JOURNAL, 2013, 27
12345